Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tolterodine
Drug ID BADD_D02244
Description Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
Indications and Usage For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Marketing Status approved; investigational
ATC Code G04BD07
DrugBank ID DB01036
KEGG ID D00646
MeSH ID D000068737
PubChem ID 443879
TTD Drug ID D0BZ7W
NDC Product Code 13668-189; 13668-190; 0904-6592; 60687-330; 0904-6593; 65427-022; 60687-319
UNII WHE7A56U7K
Synonyms Tolterodine Tartrate | Tartrate, Tolterodine | Tolterodine | Detrol | Detrol LA | Urotrol | PHA-686464B | PHA 686464B | PHA686464B | Detrusitol | Unidet
Chemical Information
Molecular Formula C22H31NO
CAS Registry Number 124937-51-5
SMILES CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.004--Not Available
Macular degeneration06.09.03.0010.000226%Not Available
Memory impairment19.20.01.003; 17.03.02.0030.001379%
Micturition urgency20.02.02.0060.000882%
Milia23.02.03.0110.000226%Not Available
Multiple sclerosis17.16.01.001; 10.04.10.0080.000339%Not Available
Myalgia15.05.02.0010.000226%
Neoplasm malignant16.16.01.0010.000226%Not Available
Nocturia20.02.03.0010.001764%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Orthostatic hypotension24.06.03.004; 17.05.01.0200.000226%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.0100.000882%
Palpitations02.11.04.012--
Penile haemorrhage21.12.01.011; 24.07.03.018--Not Available
Penis disorder21.12.01.001--Not Available
Pollakiuria20.02.02.0070.002533%
Pruritus23.03.12.0010.002759%
Pyrexia08.05.02.0030.000565%
Rash erythematous23.03.13.0290.000226%Not Available
Rhinorrhoea22.12.03.021--
Rotator cuff syndrome12.01.07.018; 15.01.08.0020.000339%
Scab23.03.03.0040.000226%Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin fissures23.03.03.008--Not Available
Sleep disorder19.02.04.0010.000498%Not Available
Somnolence19.02.05.003; 17.02.04.0060.000724%
Swelling08.01.03.0150.000769%Not Available
Tachycardia02.03.02.0070.000678%Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene